Multiple myeloma cancer stem cells.
Gao M et al. Oncotarget. 2016 Mar 17. doi: 10.18632/oncotarget.8154. [Epub ahead of print].

Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution.
Tang M et al. Clin Cancer Res. 2016 Mar 22. pii: clincanres.2793.2015. [Epub ahead of print].

Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H et al. Ann N Y Acad Sci. 2016 Jan;1364(1):32-51. doi: 10.1111/nyas.13038.

The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E et al. Pathol Res Pract. 2016 Mar 2. pii: S0344-0338(15)30043-1. doi: 10.1016/j.prp.2015.11.021. [Epub ahead of print].

Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
Ise M et al. Clin Lymphoma Myeloma Leuk. 2016 Feb 27. pii: S2152-2650(16)00097-5. doi: 10.1016/j.clml.2016.02.037. [Epub ahead of print].

Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase.
Takeda T et al. Chem Biol Interact. 2016 Mar 17. pii: S0009-2797(16)30088-6. doi: 10.1016/j.cbi.2016.03.018. [Epub ahead of print].

Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.
Chon HJ et al. Amino Acids. 2016 Mar 19. [Epub ahead of print].

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.
Taylor-Kashton C et al. J Cell Physiol. 2016 Mar 17. doi: 10.1002/jcp.25378. [Epub ahead of print].

Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
Wilson DL et al. ACS Med Chem Lett. 2016 Jan 15;7(3):250-5. doi: 10.1021/acsmedchemlett.5b00401. eCollection 2016.

Autophagy in Plasma Cell Ontogeny and Malignancy.
Milan E et al. J Clin Immunol. 2016 Mar 16. [Epub ahead of print].

Multiple myeloma with Russell bodies and needle-shaped crystalline inclusions.
Yamada T et al. Int J Hematol. 2016 Mar 16. [Epub ahead of print].

Mesenchymal stem cells secretomes’ affect multiple myeloma translation initiation.
Marcus H et al. Cell Signal. 2016 Mar 11;28(6):620-630. doi: 10.1016/j.cellsig.2016.03.003. [Epub ahead of print].

Epigenetic regulators: Polycomb-miRNA circuits in cancer.
de Nigris F. Biochim Biophys Acta. 2016 Mar 11. pii: S1874-9399(16)30044-X. doi: 10.1016/j.bbagrm.2016.03.005. [Epub ahead of print].

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.
Binder M et al. Blood Cancer J. 2016 Mar 11;6:e401. doi: 10.1038/bcj.2016.15.

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC).
Giallongo C et al. Oncotarget. 2016 Mar 7. doi: 10.18632/oncotarget.7969. [Epub ahead of print].

Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases.
Ettari R et al. Curr Med Chem. 2016 Mar 18. [Epub ahead of print].

Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.
Asai T et al. Sci Rep. 2016 Mar 10;6:22760. doi: 10.1038/srep22760.

Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL et al. Cancer Immunol Immunother. 2016 Mar 10. [Epub ahead of print].

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E et al. Clin Cancer Res. 2016 Mar 9. pii: clincanres.2224.2015. [Epub ahead of print].

Mir-221/222 are promising targets for innovative anticancer therapy.
Di Martino MT et al. Expert Opin Ther Targets. 2016 Mar 21:1-10. [Epub ahead of print].

Multiple myeloma exosomes establish a favorable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J et al. J Pathol. 2016 Mar 9. doi: 10.1002/path.4712. [Epub ahead of print].

Monitoring protein synthesis in single live cancer cells.
Tu C et al. Integr Biol (Camb). 2016 Mar 9. [Epub ahead of print].

A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies.
Guglieri-López B et al. J Lab Autom. 2016 Mar 8. pii: 2211068216636570. [Epub ahead of print].

Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization.
Chen D et al. Immunopharmacol Immunotoxicol. 2016 Mar 8:1-9. [Epub ahead of print].

Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.
Tang CA et al. Cancer Res. 2016 Mar 7. [Epub ahead of print].

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J et al. Oncotarget. 2016 Feb 29. doi: 10.18632/oncotarget.7792. [Epub ahead of print].

The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Zangari M et al. Bone. 2016 Mar 3;86:131-138. doi: 10.1016/j.bone.2016.02.019. [Epub ahead of print].

Expression profile of BCL-2, BCL-XL and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models.
Punnoose E et al. Mol Cancer Ther. 2016 Mar 3. pii: molcanther.0730.2015. [Epub ahead of print].

Elevated Translation Initiation Factor eIF4E is an Attractive Therapeutic Target in Multiple Myeloma.
Li S et al. Mol Cancer Ther. 2016 Mar 3. pii: molcanther.0798.2015. [Epub ahead of print].

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A et al. J Hematol Oncol. 2016 Mar 2;9(1):17. doi: 10.1186/s13045-016-0247-4.

Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.
Pisklakova A et al. Cancer Biol Ther. 2016 Mar 2:0. [Epub ahead of print].

Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.
Lee D et al. J Clin Invest. 2016 Feb 29. pii: 84620. doi: 10.1172/JCI84620. [Epub ahead of print].

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.
Jung O et al. Oncogenesis. 2016 Feb 29;5:e202. doi: 10.1038/oncsis.2016.5.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.
de la Puente P et al. Blood Cancer J. 2016 Feb 26;6:e399. doi: 10.1038/bcj.2016.7.

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.
Kortuem KM et al. Blood Cancer J. 2016 Feb 26;6:e397. doi: 10.1038/bcj.2016.1.

Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
Kjeldsen E. Cancer Genomics Proteomics. 2016 03-04;13(2):91-127.